Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.

[1]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[2]  Rohit Loomba,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[3]  G. Coral,et al.  Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese. , 2018, Annals of hepatology.

[4]  Lanman Xu,et al.  The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis , 2018, Expert review of gastroenterology & hepatology.

[5]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[6]  A. Stein,et al.  Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review. , 2018, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[7]  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[8]  B. Hoogwerf,et al.  Non‐alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[9]  K. Clément,et al.  Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study , 2017, Diabetologia.

[10]  K. Cusi,et al.  Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease , 2017, Hepatology.

[11]  E. Disse,et al.  EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? , 2017, Diabetologia.

[12]  B. Balkau,et al.  Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies , 2017, Journal of hypertension.

[13]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[14]  K. Clément,et al.  Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity , 2016, Gut.

[15]  M. Orešič,et al.  Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .

[16]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[17]  F. Santini,et al.  SIO management algorithm for patients with overweight or obesity: consensus statement of the Italian Society for Obesity (SIO) , 2016, Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.

[18]  A. Gastaldelli,et al.  Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease , 2016, Hepatology.

[19]  Stuart K. Roberts,et al.  Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese , 2016, Obesity Surgery.

[20]  A. Gastaldelli,et al.  The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis , 2015, Nutrients.

[21]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[22]  Anthony Petrick,et al.  Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients , 2015, Obesity Surgery.

[23]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[24]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[25]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[26]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[27]  J. Oppert,et al.  Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery , 2014, Obesity Surgery.

[28]  S. Verma,et al.  Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD) , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[29]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[30]  Z. Halpern,et al.  Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. , 2012, Journal of hepatology.

[31]  K. Clément,et al.  Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data , 2012, PloS one.

[32]  W. Rathmann,et al.  Association between Markers of Fatty Liver Disease and Impaired Glucose Regulation in Men and Women from the General Population: The KORA-F4-Study , 2011, PloS one.

[33]  A. Mari,et al.  Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes , 2011, Diabetologia.

[34]  B. Balkau,et al.  Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women , 2011, Diabetes.

[35]  M. Burotto,et al.  Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients , 2010, Obesity surgery.

[36]  F. Pattou,et al.  Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.

[37]  Beverley Balkau,et al.  Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population , 2009, Hepatology.

[38]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[39]  J. Girard,et al.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. , 2008, The Journal of clinical investigation.

[40]  M. Matsuda,et al.  Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test , 2007, Diabetes Care.

[41]  G. Marchesini,et al.  Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease , 2007, Gut.

[42]  H. Cortez‐Pinto,et al.  Hepatic histology in obese patients undergoing bariatric surgery. , 2006, Journal of hepatology.

[43]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[44]  T. Omatsu,et al.  The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease , 2006, Annals of Internal Medicine.

[45]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[46]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[47]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[48]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[49]  NIH consensus statement covers treatment of obesity. , 1991, American family physician.